Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03285672 · ClinicalTrials.gov registry record · Phase 2
FP-101 for the Treatment of Hot Flashes in Postmenopausal Women
A Phase 2 study, sponsored by Fervent Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
NCT03285672 is a Phase 2 study that has completed, run by Fervent Pharmaceuticals. The registered enrollment target is 109 participants.
The verdict
NCT03285672, a Phase 2 study, has completed, sponsored by Fervent Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the efficacy of FP-101 versus placebo for the treatment of hot flashes in postmenopausal women.
Interventions
- DRUG Placebo Comparator
- DRUG FP-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2018-03-26 |
| Est. Completion | 2018-10-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03285672
The ClinicalTrials.gov registry entry for NCT03285672 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fervent Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT03285672 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03285672 about?
NCT03285672 is a clinical study titled "FP-101 for the Treatment of Hot Flashes in Postmenopausal Women". The purpose of the study is to determine the efficacy of FP-101 versus placebo for the treatment of hot flashes in postmenopausal women.
What is the current status of trial NCT03285672?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2018-03-26. Estimated completion is 2018-10-29.
What interventions are being tested in trial NCT03285672?
The interventions under investigation include: Placebo Comparator (DRUG), FP-101 (DRUG).
Who is sponsoring clinical trial NCT03285672?
This trial is sponsored by Fervent Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.